Gyre Therapeutics
GYRE
42 hedge funds and large institutions have $36.5M invested in Gyre Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 13 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0.09% less ownership
Funds ownership: 8.34% → 8.26% (-0.09%)
14% less funds holding
Funds holding: 49 → 42 (-7)
34% less capital invested
Capital invested by funds: $55.3M → $36.5M (-$18.8M)
35% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 17
50% less call options, than puts
Call options by funds: $15K | Put options by funds: $30K
54% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 13
Top Buyers
| 1 |
2L
22NW LP
Seattle,
Washington
|
+$3.31M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.73M |
| 3 |
Millennium Management
New York
|
+$963K |
| 4 |
FM
Fondren Management
Houston,
Texas
|
+$642K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$146K |
Top Sellers
| 1 |
SCM
Sio Capital Management
New York
|
-$2.05M |
| 2 |
Morgan Stanley
New York
|
-$1.36M |
| 3 |
Goldman Sachs
New York
|
-$642K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$476K |
| 5 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$471K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| – | -$28.4K | -527 | -98% |
|
52
Legal & General Group
London,
United Kingdom
| – | -$13K | -236 | Closed |
|
|
AG
53
Advisor Group
Phoenix,
Arizona
| – | -$1K | -25 | Closed |
|
|
PCP
54
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -18 | Closed |
|
GYRE Hedge Fund Activity: Q3 2019 in Review
42 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2019, worth a combined $36.5M — down 34% from $55.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GYRE and 6 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 11 added.
The largest buyer was 22NW LP, adding an estimated $3.31M. The largest seller was Sio Capital Management, cutting an estimated $2.05M.
- 42 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2019, down from 49 in Q2 2019.
- Funds reported $36.5M of Gyre Therapeutics stock for Q3 2019, down 34% quarter-over-quarter.
- 6 funds opened new Gyre Therapeutics positions in Q3 2019 and 13 closed out, a net change of -7 holders.
- The largest Gyre Therapeutics buyer in Q3 2019 was 22NW LP, an estimated $3.31M added.
- The largest Gyre Therapeutics seller in Q3 2019 was Sio Capital Management, an estimated $2.05M sold.
Based on aggregated 13F filings for Q3 2019.